Please ensure Javascript is enabled for purposes of website accessibility

Marijuana Investing in 2017: 5 Numbers Everyone Should Know

By Keith Speights - Updated Mar 8, 2018 at 10:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With the legalization movement accelerating, and pharmaceutical companies working hard to get THC-based medicines approved, marijuana could be a growth industry. But the risks are still significant.

Many marijuana stocks have soared in 2016, with one enjoying especially impressive gains of well over 2,000%. However, this speculative industry is fraught with risk. If you're considering investing in marijuana stocks in the new year, here are five numbers you should know before taking the plunge.

A marijuana leaf

Image source: Getty Images.

$50 billion

Ackrell Capital projects that the market for cannabinoid-based pharmaceuticals will top $50 billion annually. Before you get too excited, though, read the fine print. The investment firm notes that the market won't develop until after the end of "prohibition"  -- i.e. the lifting of federal laws against use of marijuana.

Assuming federal laws do indeed change, is this estimate realistic? Possibly. Cannabinoids have been found to have potential as treatments in over 40 medical indications, including cancer, chronic pain, epilepsy, and glaucoma.

One experimental drug for just one of those indications could reach peak annual sales of $3 billion if the most optimistic projections become reality. Elemer Piros with Roth Capital Partners thinks that GW Pharmaceuticals' (GWPH) Epidiolex, which is in late-stage clinical studies targeting treatment of two rare forms of epilepsy, could ultimately generate annual sales in that vicinity if approved.  


Support for use of medical marijuana is growing quickly. After the U.S. elections in November, 28 states plus the District of Columbia now allow legal use of medical marijuana. A few also allow recreational use of the drug.

Infographic: The States Where It's Legal To Smoke Marijuana | Statista

Image source: Statista.

This increased acceptance should diminish the barriers for companies operating in the marijuana industry. And that presents opportunities for investors.


While the opportunities exist, the current realities are stark. The U.S. Food and Drug Administration has approved a grand total of three cannabinoid drugs.

Marinol, which is now marketed by AbbVie (ABBV -0.63%), was approved  way back in 1985 for treating nausea and vomiting associated with cancer chemotherapy. The drug's active ingredient is dronabinol, a man-made form of THC, which is considered the psychoactive component of marijuana. 

The FDA also approved another cannabinoid, Cesamet, in 1985. However, that drug was removed from the U.S. market in 1989 for "commercial reasons." Valeant Pharmaceuticals (BHC 9.18%) later bought Cesamet and brought the drug back to market in 2006.

It took quite a while for another cannabinoid to join Marinol and Cesamet. In July of this year, the FDA gave a thumbs-up for Insys Therapeutics' (INSY) Syndros. As with Marinol, the active ingredient of Syndros is dronabinol. While Marinol is available as a capsule, Syndros is a liquid formulation. 


A very important number for investors considering investing in marijuana is how many attorney generals the U.S. federal government has: exactly one. And the person who appears to be getting the nomination to fill that role in 2017, Alabama Republican Sen. Jeff Sessions, is an adamant opponent of legalized marijuana.

Gavel and law books

Image source: Getty Images.

Sessions publicly chastised the Obama administration for failing to enforce federal marijuana restrictions. He has also stated that marijuana reform was "a tragic mistake." Should Sessions win confirmation, he could choose to clamp down on the growing marijuana industry with the stroke of a pen.

Will he do so? No one knows. President-elect Trump has expressed support for the use of medical marijuana, and stated that the issue should be decided at the state level. 


It has been said that the best way to get rich during a gold rush is to sell shovels. With that in mind, perhaps the best figure for investors looking to make money from the "marijuana rush" is the number zero. Companies that have zero marijuana-related products, but that have the potential to benefit by serving those that do might be the smartest marijuana investing play of all.

One possibility is Scotts Miracle-Gro (SMG 0.60%). The company has acquired several leaders in hydroponics and has positioned itself as the premier supplier for indoor marijuana growers. Scotts generated revenue of over $2.8 billion last year, although less than 10% of that total stemmed from its hydroponics business. 

Let's suppose that Sessions becomes attorney general, but doesn't disrupt what the states are doing with regards to legalization of marijuana. Let's say the FDA approves more cannabinoid drugs. Let's assume that medical marijuana becomes a $50 billion industry as some project. AbbVie and Valeant won't be the biggest winners, for sure. What about GW Pharmaceuticals or Insys? Probably not, either.

If all that happens, a lot more marijuana will need to be grown. And plenty of hydroponics products will be needed. Scotts just might be the best marijuana investment around, even though the company doesn't have any marijuana products at all. Zero is a great number to know if you're looking to invest in marijuana in 2017.

Marijuana stocks have been hotter than a firecracker lit at both ends. Are they the right investment for you?

Keith Speights has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
$5.59 (9.18%) $0.47
The Scotts Miracle-Gro Company Stock Quote
The Scotts Miracle-Gro Company
$80.75 (0.60%) $0.48
AbbVie Inc. Stock Quote
AbbVie Inc.
$138.04 (-0.63%) $0.88
INSYS Therapeutics Stock Quote
INSYS Therapeutics
GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.